Pharmeuropa: Revised Chapter 2.9.3. Dissolution Test for Solid Dosage Forms published for comment
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
In the Pharmeuropa issue 35.1, a proposal for a revised chapter 2.9.3. Dissolution test for solid dosage forms was published. The deadline for submitting comments is 31 March 2023.
Compared to the monograph published in the 11th Edition of the Ph. Eur., the following changes are proposed:
- "The text has been edited to improve its clarity and to harmonise the terminology;
- the temperature requirement for the dissolution medium is now given with one digit after the decimal point to be consistent with the required accuracy requirement;
- the requirement for the pH value of the buffer solutions is now stated with two digits after the decimal point to be consistent with the required accuracy requirement;
- the section entitled Apparatus 3 (under Procedure) has been updated to indicate that the apparatus can be operated in two different ways (a) by conducting the test in one vessel or (b) by conducting the test using consecutive vessels."
The full text and further details on the revision and can be found, after registration, on the Pharmeuropa website.
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


